Antares to start phase 3 Anturol trial, plans to file NDA soon

By Elaine Rigoli

Tampa, Fla., Sept. 28 - Antares Pharma, Inc. said it finished the phase 2 trial for Anturol, with no skin irritants reported with the highest dosage, and will pursue a New Drug Application regulatory pathway with the Food and Drug Administration.

The company plans to begin enrollment for a phase 3 trial of Anturol shortly.

Anturol is a gel-based transdermal treatment for overactive bladder. Anturol is a gel formulation of oxybutynin designed for optimized absorption through the skin following once-a-day application on the abdomen, shoulders or thighs.

The Ewing, N.J.-based biopharmaceutical company's president and chief executive officer, Jack Stover, said the company has more than a $60 million market cap, no debt or preferred stock and 53 million shares outstanding.

Stover spoke at the UBS Global Life Sciences Conference in New York.

The company added that its 2006 accomplishments included raised capital, increased sales, solid regulatory and commercial progress and an expanded pipeline.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.